Publications

• Tirzepatide for Obesity Treatment and Diabetes Prevention.Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I. N Engl J Med. 2024 Nov 13; 2024 Nov 13. PMID: 39536238.
• Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, Ajaz Hussain S, Pedersen SD, Borowska L, Unseld A, Kloer IM, Kaplan LM. Obesity (Silver Spring). 2024 Nov 4; 2024 Nov 4. PMID: 39495965.
• Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings.Kelly AS, Bahlke M, Baker JL, de Beaufort C, Belin RM, Fonseca H, Hale PM, Holm JC, Hsia DS, Jastreboff AM, Juliusson PB, Murphy M, Pak J, Paul E, Rudolph B, Srivastava G, Tornøe CW, Weghuber D, Fox CK. Pediatr Obes. 2024 Nov; 2024 Sep 17. PMID: 39289849.
• Ending Weight Stigma to Advance Health Equity.Pearl RL, Donze LF, Rosas LG, Agurs-Collins T, Baskin ML, Breland JY, Byker Shanks C, Cooksey Stowers K, Johnson S, Lee BY, Martin MY, Mujuru P, Odoms-Young A, Panza E, Pronk NP, Calicutt K, Nadglowski J, Nece PM, Tedder M, Chow LS, Krishnamurti H, Jay M, Xi D, Jastreboff AM, Stanford FC. Am J Prev Med. 2024 Nov; 2024 Jun 28. PMID: 38945180.
• Eligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity.Chetty AK, Khunte M, Chen AS, Jastreboff AM, Krumholz HM, Lu Y. J Gen Intern Med. 2024 Oct 30; 2024 Oct 30. PMID: 39477867.
• GLP-1 programs the neurovascular landscape.Chen B, Yu X, Horvath-Diano C, Ortuño MJ, Tschöp MH, Jastreboff AM, Schneeberger M. Cell Metab. 2024 Oct 1. PMID: 39357509.
• DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Cherney DZI, DeFronzo RA, Del Prato S, Eckel RH, Filippatos G, Fonarow GC, Fonseca VA, Garvey WT, Giorgino F, Grant PJ, Green JB, Greene SJ, Groop PH, Grunberger G, Jastreboff AM, Jellinger PS, Khunti K, Klein S, Kosiborod MN, Kushner P, Leiter LA, Lepor NE, Mantzoros CS, Mathieu C, Mende CW, Michos ED, Morales J, Plutzky J, Pratley RE, Ray KK, Rossing P, Sattar N, Schwarz PEH, Standl E, Steg PG, Tokgözoğlu L, Tuomilehto J, Umpierrez GE, Valensi P, Weir MR, Wilding J, Wright EE Jr. Metabolism. 2024 Oct; 2024 Jun 7. PMID: 38852020.
• Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, Kushner RF, Lingvay I, Burguera B, Gajos G, Horn DB, Hramiak IM, Jastreboff AM, Kokkinos A, Maeng M, Matos ALSA, Tinahones FJ, Lincoff AM, Ryan DH. Diabetes Care. 2024 Aug 1. PMID: 38907683.
• Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey.Lu Y, Liu Y, Jastreboff AM, Khera R, Ndumele CD, Rodriguez F, Watson KE, Krumholz HM. Circ Cardiovasc Qual Outcomes. 2024 Jan; 2023 Nov 11. PMID: 37950677.
• Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, McKee SA. Obesity (Silver Spring). 2023 Nov; 2023 Sep 26. PMID: 37751990.
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.Jastreboff AM, Kaplan LM, Hartman ML. N Engl J Med. 2023 Oct 26. PMID: 37888927.
• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM. Lancet. 2023 Aug 19; 2023 Jun 26. PMID: 37385275.
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. N Engl J Med. 2023 Aug 10; 2023 Jun 26. PMID: 37366315.
• Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.Kelly AS, Arslanian S, Hesse D, Iversen AT, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff AM. Obesity (Silver Spring). 2023 Aug; 2023 Jul 9. PMID: 37196421.
• New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics.Jastreboff AM, Kushner RF. Annu Rev Med. 2023 Jan 27. PMID: 36706749.
• Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society.Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Am J Kidney Dis. 2022 Dec; 2022 Oct 21. PMID: 36280397.
• Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society.Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obesity (Silver Spring). 2022 Dec; 2022 Oct 21. PMID: 36268562.
• Tirzepatide Once Weekly for the Treatment of Obesity. Reply.Jastreboff AM, Aronne LJ, Stefanski A. N Engl J Med. 2022 Oct 13. PMID: 36239655.
• Tirzepatide Once Weekly for the Treatment of Obesity.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. N Engl J Med. 2022 Jul 21; 2022 Jun 4. PMID: 35658024.
• Stress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating.Bini J, Parikh L, Lacadie C, Hwang JJ, Shah S, Rosenberg SB, Seo D, Lam K, Hamza M, De Aguiar RB, Constable T, Sherwin RS, Sinha R, Jastreboff AM. Neuroimage Clin. 2022; 2022 Sep 16. PMID: 36126514.
• Lower synaptic density is associated with psychiatric and cognitive alterations in obesity.Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, Pietrzak RH, Esterlis I. Neuropsychopharmacology. 2022 Jan; 2021 Jul 22. PMID: 34294874.
• Impact of Obesity on Heart Transplantation Outcomes.Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, Mori M, Clark KA, Miller PE, Fuery MA, Rogers JG, Notarianni A, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T, Mullan CW. J Am Heart Assoc. 2021 Dec 7; 2021 Dec 2. PMID: 34854316.
• Treating the Chronic Disease of Obesity.Gossmann M, Butsch WS, Jastreboff AM. Med Clin North Am. 2021 Nov. PMID: 34688422.
• COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society.Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Stanford FC, Zeltser LM, Kotz CM, Jastreboff AM. Obesity (Silver Spring). 2021 Oct; 2021 Sep 13. PMID: 34212511.
• Addressing psychosocial health in the treatment and care of adolescents with obesity.Jebeile H, Cardel MI, Kyle TK, Jastreboff AM. Obesity (Silver Spring). 2021 Sep. PMID: 34431234.
• Dietary supplements and alternative therapies for obesity: A Perspective from The Obesity Society's Clinical Committee.Kidambi S, Batsis JA, Donahoo WT, Jastreboff AM, Kahan S, Saunders KH, Heymsfield SB. Obesity (Silver Spring). 2021 Jul. PMID: 34159756.
• Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study.Bini J, Bhatt S, Hillmer AT, Gallezot JD, Nabulsi N, Pracitto R, Labaree D, Kapinos M, Ropchan J, Matuskey D, Sherwin RS, Jastreboff AM, Carson RE, Cosgrove K, Huang Y. Mol Imaging Biol. 2020 Aug. PMID: 32133575.
• Treatment of Adolescent Obesity in 2020.Cardel MI, Jastreboff AM, Kelly AS. JAMA. 2019 Nov 5. PMID: 31566652.
• COMMENTARY FROM THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS ON THE U.S. PREVENTIVE SERVICES TASK FORCE RECOMMANDATIONS REGARDING WEIGHT LOSS INTERVENTIONS.Garvey WT, Jastreboff AM. Endocr Pract. 2019 Apr; 2019 Apr 23. PMID: 31013160.
• Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity.Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, Pratt JSA, Bolling C, Michalsky MP, Cook S, Lenders CM, Apovian CM. Obesity (Silver Spring). 2019 Feb. PMID: 30677262.
• Obesity as a Disease: The Obesity Society 2018 Position Statement.Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity (Silver Spring). 2019 Jan. PMID: 30569641.
• Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study.Jastreboff AM, Chaplin TM, Finnie S, Savoye M, Stults-Kolehmainen M, Silverman WK, Sinha R. J Pediatr. 2018 Nov; 2018 Sep 18. PMID: 30241766.
• Stress, cortisol, and other appetite-related hormones: Prospective prediction of 6-month changes in food cravings and weight.Chao AM, Jastreboff AM, White MA, Grilo CM, Sinha R. Obesity (Silver Spring). 2017 Apr. PMID: 28349668.
• Elevated Dopamine D(2/3) Receptor Availability in Obese Individuals: A PET Imaging Study with [(11)C](+)PHNO.Gaiser EC, Gallezot JD, Worhunsky PD, Jastreboff AM, Pittman B, Kantrovitz L, Angarita GA, Cosgrove KP, Potenza MN, Malison RT, Carson RE, Matuskey D. Neuropsychopharmacology. 2016 Dec; 2016 Jul 4. PMID: 27374277.
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at https://www.aace.com/publications/guidelines.Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R. Endocr Pract. 2016 Jul. PMID: 27472012.
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R. Endocr Pract. 2016 Jul; 2016 May 24. PMID: 27219496.
• Altered Brain Response to Drinking Glucose and Fructose in Obese Adolescents.Jastreboff AM, Sinha R, Arora J, Giannini C, Kubat J, Malik S, Van Name MA, Santoro N, Savoye M, Duran EJ, Pierpont B, Cline G, Constable RT, Sherwin RS, Caprio S. Diabetes. 2016 Jul; 2016 Apr 5. PMID: 27207544.
• Blunted suppression of acyl-ghrelin in response to fructose ingestion in obese adolescents: the role of insulin resistance.Van Name M, Giannini C, Santoro N, Jastreboff AM, Kubat J, Li F, Kursawe R, Savoye M, Duran E, Dziura J, Sinha R, Sherwin RS, Cline G, Caprio S. Obesity (Silver Spring). 2015 Mar; 2015 Feb 3. PMID: 25645909.
• Leptin is associated with exaggerated brain reward and emotion responses to food images in adolescent obesity.Jastreboff AM, Lacadie C, Seo D, Kubat J, Van Name MA, Giannini C, Savoye M, Constable RT, Sherwin RS, Caprio S, Sinha R. Diabetes Care. 2014 Nov; 2014 Aug 19. PMID: 25139883.
• Sex differences in the association between dietary restraint, insulin resistance and obesity.Jastreboff AM, Gaiser EC, Gu P, Sinha R. Eat Behav. 2014 Apr; 2014 Mar 26. PMID: 24854820.
• Stress as a common risk factor for obesity and addiction.Sinha R, Jastreboff AM. Biol Psychiatry. 2013 May 1; 2013 Mar 26. PMID: 23541000.
• Comparison of BMI and physical activity between old order Amish children and non-Amish children.Hairston KG, Ducharme JL, Treuth MS, Hsueh WC, Jastreboff AM, Ryan KA, Shi X, Mitchell BD, Shuldiner AR, Snitker S. Diabetes Care. 2013 Apr; 2012 Oct 23. PMID: 23093661.
• Neural correlates of stress- and food cue-induced food craving in obesity: association with insulin levels.Jastreboff AM, Sinha R, Lacadie C, Small DM, Sherwin RS, Potenza MN. Diabetes Care. 2013 Feb; 2012 Oct 15. PMID: 23069840.
• Body mass index, metabolic factors, and striatal activation during stressful and neutral-relaxing states: an FMRI study.Jastreboff AM, Potenza MN, Lacadie C, Hong KA, Sherwin RS, Sinha R. Neuropsychopharmacology. 2011 Feb; 2010 Nov 3. PMID: 21048702.